Navamedic Past Earnings Performance

Past criteria checks 1/6

Navamedic has been growing earnings at an average annual rate of 57.2%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been growing at an average rate of 24.8% per year. Navamedic's return on equity is 7.4%, and it has net margins of 3.7%.

Key information

57.2%

Earnings growth rate

72.4%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth rate24.8%
Return on equity7.4%
Net Margin3.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Navamedic makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0FDB Revenue, expenses and earnings (NOK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2452620690
30 Jun 2454327670
31 Mar 24511-11680
31 Dec 235123640
30 Sep 2350331800
30 Jun 23454231010
31 Mar 2344143570
31 Dec 2238229480
30 Sep 2235612590
30 Jun 223278470
31 Mar 222834490
31 Dec 212781440
30 Sep 21244-7500
30 Jun 21237-6380
31 Mar 21213-8460
31 Dec 20210-16330
30 Sep 20202-22580
30 Jun 20194-24330
31 Mar 20199-26340
31 Dec 19189-16330
30 Sep 19193-1320
30 Jun 191890270
31 Mar 1918710250
31 Dec 181844260
30 Sep 18177-20300
30 Jun 18178-13280
31 Mar 18222-20300
31 Dec 17258-16300
30 Sep 172943310
30 Jun 173154320
31 Mar 17292-9310
31 Dec 16274-11310
30 Sep 16258-28310
30 Jun 16254-30300
31 Mar 16247-17280
31 Dec 15248-11260
30 Sep 15245-4230
30 Jun 152421210
31 Mar 152421200
31 Dec 14223-1190
30 Sep 142041190
30 Jun 14182-2190
31 Mar 14161-3200
31 Dec 13152-1200

Quality Earnings: 0FDB has a large one-off loss of NOK11.3M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 0FDB's current net profit margins (3.7%) are lower than last year (6.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0FDB has become profitable over the past 5 years, growing earnings by 57.2% per year.

Accelerating Growth: 0FDB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 0FDB had negative earnings growth (-36.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (4.5%).


Return on Equity

High ROE: 0FDB's Return on Equity (7.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies